NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. Kindred Biosciences had a negative return on equity of 58.86% and a negative net margin of 1,461.28%. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 equities research analysts have issued twelve-month price targets for Kindred Biosciences' shares. Their forecasts range from $8.50 to $25.00. On average, they expect Kindred Biosciences' share price to reach $14.44 in the next year. This suggests a possible upside of 52.6% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Media coverage about KIN stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 671,100 shares, a decrease of 5.5% from the November 28th total of 709,900 shares. Based on an average trading volume of 98,200 shares, the days-to-cover ratio is currently 6.8 days. Currently, 1.8% of the company's shares are sold short. View Kindred Biosciences' Current Options Chain.

Some companies that are related to Kindred Biosciences include Innoviva (INVA), BELLUS Health (BLUSF), Y-mAbs Therapeutics (YMAB), Amneal Pharmaceuticals (AMRX), TG Therapeutics (TGTX), Esperion Therapeutics (ESPR), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Endo International (ENDP), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.46.

Kindred Biosciences has a market capitalization of $369.79 million and generates $1.97 million in revenue each year. The biopharmaceutical company earns $-49,690,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Kindred Biosciences employs 146 workers across the globe.View Additional Information About Kindred Biosciences.

The official website for Kindred Biosciences is http://kindredbio.com/.

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]